Abstract
Complex diseases, with many associated genetic and environmental factors, are a challenging target for genomic risk assessment. Genome-wide association studies (GWAS) associate disease status with, and compute risk from, individual common variants, which can be problematic for diseases with many interacting or rare variants. In addition, GWAS typically employ a reference genome which is not built from the subjects of the study, whose genetic background may differ from the reference and whose genetic characterization may be limited. We present a complementary method based on disease association with collections of genotypes, called frequented regions, on a pangenomic graph built from subjects’ genomes. We introduce the pangenomic genotype graph, which is better suited than sequence graphs to human disease studies. Our method draws out collections of features, across multiple genomic segments, which are associated with disease status. We show that the frequented regions method consistently improves machine-learning classification of disease status over GWAS classification, allowing incorporation of rare or interacting variants. Notably, genomic segments that have few or no variants of genome-wide signif-icance (p < 5 × 10−8) provide much-improved classification with frequented regions, encouraging their application across the entire genome. Frequented regions may also be utilized for purposes such as choice of treatment in addition to prediction of disease risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partially funded by internal funds at The National Center for Genome Resources, plus a small external portion from NSF award #1759522. The authors received no payment or services outside of those sources.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB required; dbGaP data used under General Research Use permission given by the appropriate dbGaP committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The case-control data used are available from dbGaP and the 1000 Genomes Consortium, the latter publicly available, the former requiring dbGaP approval. The dbGaP accessions used are phs001071.v1.p1 and phs000473.v2.p2. The code written and used is publicly available on GitHub under the repositories sammyjava/GWAS and sammyjava/pangenomics.
https://github.com/sammyjava/GWAS
https://github.com/sammyjava/pangenomics
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001071.v1.p1
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000473.v2.p2